Lead Sponsor

BeiGene

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Signed informed consent form (ICF) and ability to comply with study requirements
•2. Age ≥ 12 months at consent
•3. Diagnosis of high-risk neuroblastoma according to the International Neuroblastoma Staging System (INSS) criteria.
•4. Participants who have previously received induction chemotherapy and achieved a partial or complete response followed by myeloablative therapy and stem cell transplantation. Stem cell transplantation should be completed within 120 days of dinutuximab beta first administration

•1. Hypersensitivity to ≥ 1 component of dinutuximab beta antibody or against mouse proteins
•2. Actively progressive disease (not stabilized) or recurrent disease at the time of inclusion into the study
•3. Previous treatment with anti-GD2 antibody before enrolling in this study